RaySearch Laboratories AB (STO:RAYB) announced on Thursday that The Swiss Medical Network has signed a multi-system agreement for Accuray Inc's (Nasdaq:ARAY) radiation therapy systems and RaySearch's treatment planning system (TPS) and oncology information system (OIS).
Reportedly, this is the first multi-system agreement by a hospital for both Accuray and RaySearch products. Financial details of the agreement were not available.
This purchase includes the Accuray Radixact and CyberKnife M6 Systems, as well as the RaySearch RayStation TPS and RayCare OIS.
It is expected that together, these complementary systems will help enable The Swiss Medical Network team to provide optimal treatments for patients who may benefit from highly precise radiation therapy.
The first patient treatments using the combination of the Radixact System and RayStation by the Swiss Medical Network are anticipated to take place in 2020.
Also, The Swiss Medical Network, Accuray and RaySearch have partnered to expand opportunities for training healthcare professionals on the latest technologies.
Accuray and RaySearch will collaborate on a new training facility where healthcare professionals from around the world will have the opportunity to learn from peers and receive education on the Radixact and CyberKnife M6 Systems, as well as RayStation TPS and RayCare OIS.
This state-of-the-art training facility, unique in Europe, will enable participating companies to further develop the late stages of their research programmes through direct contact with doctors and patients of the Genolier Clinic, the flagship clinic of the Swiss Medical Network, located in Genolier, Switzerland.
This training facility will be built adjacent to the Genolier Clinic, on the Swiss Medical Technopark campus.
RaySearch, a developer of software solutions to improve cancer care, markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide.
Accuray develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalised and more effective.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886